Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
Haussmann J, Tamaskovics B, Bölke E, Djiepmo-Njanang FJ, Kammers K, Corradini S, Hautmann M, Ghadjar P, Maas K, Schuler PJ, Hoffmann TK, Lammering G, Budach W, Matuschek C. Haussmann J, et al. Among authors: ghadjar p. Strahlenther Onkol. 2019 Dec;195(12):1041-1049. doi: 10.1007/s00066-019-01511-z. Epub 2019 Oct 4. Strahlenther Onkol. 2019. PMID: 31586229 Review. English.
Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Ghadjar P, et al. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. doi: 10.1016/j.ijrobp.2010.11.067. Epub 2011 Feb 16. Int J Radiat Oncol Biol Phys. 2012. PMID: 21300466 Clinical Trial.
Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J, Studer G, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Ghadjar P, et al. Radiother Oncol. 2012 Aug;104(2):213-8. doi: 10.1016/j.radonc.2012.05.004. Epub 2012 Jun 21. Radiother Oncol. 2012. PMID: 22726581 Clinical Trial.
Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer.
Brömme JO, Schmücking M, Arnold A, Giger R, Rauch D, Leiser D, Plasswilm L, Geretschläger A, Ghadjar P, Aebersold DM. Brömme JO, et al. Among authors: ghadjar p. Strahlenther Onkol. 2013 Aug;189(8):618-24. doi: 10.1007/s00066-013-0397-z. Epub 2013 Jul 4. Strahlenther Onkol. 2013. PMID: 23821138 Free article. Clinical Trial.
Regional nodal relapse in surgically staged Merkel cell carcinoma.
Hoeller U, Mueller T, Schubert T, Budach V, Ghadjar P, Brenner W, Kiecker F, Schicke B, Haase O. Hoeller U, et al. Among authors: ghadjar p. Strahlenther Onkol. 2015 Jan;191(1):51-8. doi: 10.1007/s00066-014-0756-4. Epub 2014 Oct 8. Strahlenther Onkol. 2015. PMID: 25293726 Clinical Trial.
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Budach V, et al. Among authors: ghadjar p. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24. doi: 10.1016/j.ijrobp.2014.12.034. Epub 2015 Feb 7. Int J Radiat Oncol Biol Phys. 2015. PMID: 25670541 Clinical Trial.
Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients: Differences in dose distributions and potential implications for clinical practice.
Stromberger C, Ghadjar P, Marnitz S, Thieme AH, Jahn U, Raguse JD, Karaj-Rossbacher E, Böttcher A, Jamil B, Budach V. Stromberger C, et al. Among authors: ghadjar p. Strahlenther Onkol. 2016 Jan;192(1):17-24. doi: 10.1007/s00066-015-0913-4. Strahlenther Onkol. 2016. PMID: 26462675
176 results